- Home
- MYGN vs OMI Comparison
MYGN vs OMI Comparison
Compare MYGN & OMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- OMI
- Stock Information
- Founded
- MYGN 1991
- OMI 1882
- Country
- MYGN United States
- OMI United States
- Employees
- MYGN N/A
- OMI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OMI Medical Specialities
- Sector
- MYGN Health Care
- OMI Health Care
- Exchange
- MYGN Nasdaq
- OMI Nasdaq
- Market Cap
- MYGN 1.2B
- OMI 1.0B
- IPO Year
- MYGN 1995
- OMI N/A
- Fundamental
- Price
- MYGN $14.18
- OMI $6.23
- Analyst Decision
- MYGN Hold
- OMI Buy
- Analyst Count
- MYGN 13
- OMI 6
- Target Price
- MYGN $22.54
- OMI $17.58
- AVG Volume (30 Days)
- MYGN 1.2M
- OMI 1.6M
- Earning Date
- MYGN 02-24-2025
- OMI 02-28-2025
- Dividend Yield
- MYGN N/A
- OMI N/A
- EPS Growth
- MYGN N/A
- OMI N/A
- EPS
- MYGN N/A
- OMI N/A
- Revenue
- MYGN $823,600,000.00
- OMI $10,660,960,000.00
- Revenue This Year
- MYGN $13.60
- OMI $4.54
- Revenue Next Year
- MYGN $3.25
- OMI $3.80
- P/E Ratio
- MYGN N/A
- OMI N/A
- Revenue Growth
- MYGN 12.15
- OMI 4.22
- 52 Week Low
- MYGN $12.04
- OMI $6.07
- 52 Week High
- MYGN $29.30
- OMI $28.35
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- OMI 11.67
- Support Level
- MYGN $14.13
- OMI $14.65
- Resistance Level
- MYGN $15.47
- OMI $15.54
- Average True Range (ATR)
- MYGN 0.72
- OMI 0.72
- MACD
- MYGN 0.27
- OMI -0.31
- Stochastic Oscillator
- MYGN 61.38
- OMI 2.24
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.